Susanne Caspar – CEO, Linnea
Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has…
Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across…
Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how…
In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production…
Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be…
Animal testing for medicinal purposes is back under the spotlight in Switzerland after a petition against the practice filed in Bern managed to generate tens of thousands of signatures. Even…
Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement and pricing, his experience of bringing CAR-T therapies to…
In February 2020, US giant MSD announced the launch of a new site in Zurich specialising in R&D, data management, and commercialisation, foregrounding the company’s commitment to Switzerland. MSD employs…
Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication perspective, the increasing importance being given to mental health by the…
Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses the evolution of the biotech sector in Switzerland, how the…
Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain Project, dives into the non-profit organization’s role in rethinking the…
In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine Venture Partners, a venture capital (VC) firm aiming to support founders and start-ups in Europe, highlighted how the European VC…
See our Cookie Privacy Policy Here
